WuXi XDC, a China-based CRDMO specialising in antibody drug conjugates (ADCs) and the broader bioconjugate market, has entered into a memorandum of understanding (MoU) with South Korea's IntoCell.
Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.
LimmaTech Biologics and AbVacc have entered into a licensing agreement, under which the former will get exclusive rights for the continued development of the latter's multivalent toxoid vaccine candidate, LBT-SA7 (previously known as IBT-V02).
Aldevron, a US-based developer and manufacturer of plasmid DNA, RNA and proteins for the biotech industry, has signed an agreement with US-based enzyme engineering company Codexis to acquire global exclusive license to Codex HiCap RNA Polymerase.
Pharmaceutical company focused on medical dermatology Almirall has signed a multi-target alliance with mRNA/LNP technology platform company etherna to discover and develop new mRNA-based therapies to address severe skin diseases, including non-melanoma skin cancer.
Rigel Pharmaceuticals has entered into a multi-year strategic development collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) for expanding the assessment of REZLIDHIA (olutasidenib) in acute myeloid leukaemia (AML) and other haematologic cancers.
Phenomic AI (Phenomic) has announced a research collaboration with Astellas Pharma for the development of solid tumour cell therapies.
Evommune has entered into a new strategic partnership with Accutar Biotechnology to discover new small-molecule drug candidates for chronic inflammatory diseases.
Biotechnology company Q32 Bio has signed an agreement to merge with Homology Medicines, in an all-stock transaction.
Xentria has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its anti-TNFα monoclonal antibody, XTMAB-16.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.